| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 5.49 | 188.9% | 9.8% |
| Total Income | 5.49 | 188.9% | 9.8% |
| Expenditure | 39.66 | 13.9% | 81.4% |
| PBT | -31.92 | 121.5% | |
| Net Profit | -31.92 | 23.1% | 114.1% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.02 | 22.7% | 92.5% |
LENZ Therapeutics Reports Q2 2026 Financial Results and Corporate Highlights
12 Aug 2026 · 12 Aug, 1:45 am
Summary
LENZ Therapeutics reported total revenue of $5.5 million for the second quarter of 2026, with product sales reaching over $1.7 million. The company highlighted strong patient engagement with VIZZ, noting that over 60% of ePharmacy patients purchased multiple packs and are tracking to an average of five packs annually. Key corporate developments include the launch of a telehealth channel to improve patient access and progress on international commercialization strategies, including regulatory submissions and new licensing agreements. The net loss for the quarter was $31.9 million, or $1.02 per share.
Key Highlights
- 1
LENZ Therapeutics reported total revenue of $5.5 million for Q2 2026, driven by VIZZ product sales and global license agreements.
- 2
VIZZ product sales in Q2 2026 reached over $1.7 million on approximately 27,000 packs sold, a 9% increase over Q1 2026.
- 3
Over 60% of ePharmacy patients have purchased more than one monthly pack of VIZZ since launch, with early average projected refill rates of 5 packs per year for Q4 2025 and Q1 2026 cohorts.
- 4
The company launched a telehealth prescribing option in July 2026 to accelerate patient access to VIZZ.
- 5
LENZ Therapeutics submitted a Marketing Authorization Application for VIZZ to the UK's MHRA in April 2026, following validation by the European Medicines Agency.
- 6
In June 2026, LENZ announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals for VIZZ in Australia and New Zealand.
- 7
Net loss for the three months ended June 30, 2026, was $31.9 million, or $1.02 per share, compared to a net loss of $14.9 million, or $0.53 per share, in the prior year period.
Management Comments
Eef Schimmelpennink
We are encouraged by the early refill behavior we are seeing with VIZZ. The majority of ePharmacy patients have purchased multiple monthly packs since launch, and among those patients, our Q4 2025 and Q1 2026 cohorts are tracking to average annualized utilization of five packs per patient. These trends reinforce the value VIZZ is delivering in the real world. Our focus is now on bringing more consumers into the category and making access as seamless as possible. Through telehealth, eligible consumers can be evaluated online by an independent licensed eye care professional and, if prescribed, receive VIZZ at home. Together with our national ‘Tired of Reading Glasses’ campaign, telehealth is designed to more readily convert awareness into adoption. While it is still early, the initial indicators are encouraging, and we believe we are building the foundation for sustained growth driven by consumers.
Informational and educational content only. Not investment advice.